Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific Antibody Designed to Promote Weight Loss, Prevent Muscle Loss and Weight ...

Blocking Activin-ActRII pathway could promote muscle regeneration and decrease fat mass. Laekna team is developing more drug candidates to maximize the value of targeting ActRII receptors.

In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of ...

E Nunn, N Jaiswal, M Gavin, K Uehara, M Stefkovich, K Drareni, R Calhoun, M Lee, C Holman, J Baur, S Patrick, P. Titchenell. Antibody Blockade of Activin Type II Receptors Preserves Skeletal Muscle ...

RNA was isolated after 1, 2, 4 and 8 h from the cells. The gene expression of BMP-Receptors (BMPR-Ia, BMPR-Ib, BMPRII), Activin receptors (ActR-I, ActR-IIa, ActR-IIb), Smad 1, 4, 5, 8 and the BMP ...

On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a ...

For instance, Activin A, which is predominantly encoded by inhibin β A (INHBA), has garnered significant attention due to its involvement in inflammation and fibrosis pathways. The diverse ...